VIDEO: Extended bevacizumab not beneficial in ovarian cancer
Click Here to Manage Email Alerts
In this video, Robert Coleman, MD, FACOG, FACS, chief scientific officer of US Oncology Research, discussed “hotly anticipated” results from the BOOST trial evaluating the potential benefits of extending bevacizumab therapy plus chemotherapy in newly diagnosed ovarian cancer.
The large, randomized, phase 3 trial, which was presented at the ASCO Annual Meeting, demonstrated that prolonging treatment with bevacizumab (Avastin, Genentech) from 15 to 30 months did not improve progression-free in this patient population. The same held true across subgroups studied, including patients with earlier-stage disease, Coleman noted.
Coleman said that although the strategy was not effective, it was a “very important hypothesis” because it would have changed the standard of care if it worked.
Collapse
Pfisterer J, et al. Abstract 5501. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Read more about
Click Here to Manage Email Alerts